China’s brokerages told to pause RWA tokenisation business in Hong Kong, sources say


China’s securities watchdog has advised some local brokerages to pause their real-world asset (RWA) tokenisation business in Hong Kong, said two sources, signalling Beijing’s concerns about a euphoric drive towards a booming digital assets market offshore.

The RWA tokenisation process usually converts traditional assets, such as stocks, bonds, funds and even real estate, into digital tokens traded on a blockchain. A raft of Chinese firms, including brokerages, have launched RWAs in Hong Kong over the past few months.

At least two leading brokerages had received informal guidance from the China Securities Regulatory Commission (CSRC) in recent weeks to refrain from conducting RWA business offshore, the sources said.

One of the sources said the latest regulatory guidance was aimed at strengthening risk management of a new business and making sure the claims made by companies are backed by strong, legitimate businesses.

09:07

Hong Kong charts new phase as digital asset hub with policy blueprint, says FSTB chief Chris Hui

Hong Kong charts new phase as digital asset hub with policy blueprint, says FSTB chief Chris Hui

Shares in top Chinese brokerages listed in Hong Kong, including Guotai Junan International and GF Securities, lost between 2 per cent and 7.3 per cent on Tuesday, while the broader market was down 0.9 per cent at the close of the morning session.

  • Related Posts

    China issues new safety rules for OpenClaw. Here are the dos and don’ts

    A unit of China’s Ministry of Industry and Information Technology (MIIT) has issued guidelines on best practices and prohibitions for adopting and using OpenClaw, the popular artificial intelligence agent that…

    Continue reading
    Eli Lilly boosts China footprint with US$3 billion plan to expand supply chain

    Eli Lilly has pledged an additional US$3 billion investment in China over the next decade to strengthen its local supply chain and manufacturing capabilities, deepening the footprint of foreign pharmaceutical…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *